In direct compression of immediate-release oral solid dosage forms, BlowTab sodium starch glycolate Type A is handled as a free-flowing but hygroscopic disintegrant with a bulk density of 0.60–0.85 g/cm³ and tapped density of 0.70–1.10 g/cm³ when measured under USP <616> Method II. A representative production formulation places the material at 2.0–4.0 wt% of core weight, blended with spray-dried lactose monohydrate (D50 90–120 µm, laser diffraction ISO 13320-1:2020) and microcrystalline cellulose PH102. The superdisintegrant action is not a simple swelling event: contact with water at 37±2 °C initiates rapid capillary uptake followed by anisotropic particle expansion, generating internal shear stress above the compact tensile strength. Tablets compressed on an instrumented rotary press at 8–12 kN main compression force, with pre-compression 2–4 kN, typically produce hardness values of 70–110 N and disintegration times below 5 min when tested in purified water per USP <701>. The most critical processing window occurs after the addition of magnesium stearate. When stearate is blended for more than 5 min at 0.5–1.0 wt%, dissolution at t80 in USP <711> Apparatus II at 50 rpm can shift from 12 min to 28 min in a model metformin hydrochloride formulation. Therefore, sodium starch glycolate is first distributed in a low-shear tumble mixer at 12–15 rpm for 10 min; the lubricant is added last and blended for 2–3 min. At press speeds above 60 rpm, SSG concentrations below 2.0 wt% are associated with increased ejection friction and elevated capping or laminating rejection rates on production lots, even when tablet hardness remains within release specification. This failure mode is monitored by friability testing under USP <1216> with a limit of not more than 1.0%. Lot-to-lot variability of BlowTab is assessed by pH of a 1% dispersion (5.5–7.5, USP <791>), loss on drying not more than 10.0% after drying at 130 °C to constant weight (USP <731>, Ph. Eur. 2.2.32), and particle size distribution under USP <786> or ISO 13320-1:2020, because the fines fraction below 45 µm affects blend segregation and die-fill uniformity on high-speed presses.

What restricts disintegrant efficiency in fluid-bed wet granulation when binder viscosity exceeds 350 mPa·s?

Wet granulation with sodium starch glycolate is not a single-variable problem; the granule microstructure and the point at which the disintegrant is added determine whether the final tablet disintegrates within compendial limits. In a top-spray fluid-bed granulator, an aqueous binder solution of pregelatinized starch or low-substituted hydroxypropyl cellulose with apparent viscosity above 350 mPa·s at 25 °C reduces atomization efficiency and forms dense, low-porosity granules. If the complete SSG charge of 4.0 wt% is dispersed only in the intragranular phase, the subsequent drying step removes water and collapses the swollen starch glycolate network; rehydration in the disintegration test is slowed by the hardened binder film. Tablets compressed from such granules at 10–15 kN may show disintegration times of 12–18 min in USP <701>, exceeding the 15 min acceptance criterion for uncoated tablets. The standard corrective route is split addition: 50% of the SSG is added intragranularly before granulation, and the remaining 50% is blended extragranularly after granule drying and sizing through an 800 µm screen. This split returns disintegration to 3–6 min without reducing tablet hardness below 80 N. Residual granule moisture is controlled by Ph. Eur. 2.2.32 or USP <731>; moisture above 3.0% at compression permits plastic deformation but may increase picking on concave punches. Binder viscosity is measured by a rotational viscometer at 25 °C; the 350 mPa·s threshold is not a pharmacological limit but a process threshold above which top-spray atomization and droplet spreading are impeded. For intragranular SSG, granule disintegration after drying can be assessed using a wet sieving method with an 800 µm sieve and a 5 min shaking time in water at 37 °C. Granules containing high-viscosity binders and no extragranular SSG may retain as much as 70–80% residue on the 800 µm screen, while split addition reduces residue to 10–20%. This directly addresses the conflict between granule hardness and tablet disintegration. Extragranular SSG must also be blended after the final granule-lubrication step to avoid the same hydrophobic film formation observed in direct compression.

When roller compaction is selected for moisture-sensitive formulations, ribbon density becomes the primary control variable for the efficiency of sodium starch glycolate that remains inside the compacted ribbons. Roll force in the range of 4–12 kN/cm, gap 1.0–2.5 mm, and roll speed 5–12 rpm generate ribbons with apparent density of 1.05–1.25 g/cm³. Milling through an oscillating granulator with a 0.8–1.25 mm screen produces dry granules with a bimodal size distribution; the coarse fraction above 800 µm controls flow, and the fine fraction below 180 µm contributes to compactibility. Sodium starch glycolate incorporated intragranularly at 3.0 wt% before compaction is embedded in the ribbon structure and loses much of its capillary accessibility. Tablets compressed from these granules at 12 kN often show disintegration times of 10–15 min because water cannot penetrate the dense ribbon fragments. Placing an additional 2.0–3.0 wt% SSG extragranularly after milling and before final lubricant blending restores rapid disintegration to 4–7 min in USP <701>. Ribbon porosity can be inferred from helium pycnometry or mercury intrusion porosimetry; ribbon solid fraction above 0.80 correlates with slow intragranular disintegration and poor release of active pharmaceutical ingredient in USP <711> Apparatus II. The dry granulation route is preferred when the API is hydrolytically unstable because the aqueous granulation step is eliminated; loss on drying after pre-blending can be maintained below 2.0% by pre-drying SSG at 60 °C when relative humidity exceeds 60% RH. Failure to pre-dry under high ambient relative humidity increases sticking to roll surfaces and produces a higher proportion of fines below 125 µm. This fines generation, measured by sieve analysis under USP <786>, can shift blend bulk density outside the 0.60–0.70 g/cm³ range and reduce tablet weight uniformity. Extragranular SSG is also the preferred variant when the API is highly plastic and sensitive to frictional heating. A roller-compacted intermediate with ribbon solid fraction below 0.70 may produce tablets with acceptable hardness but friability above 1.0% in USP <1216>, requiring an additional extragranular microcrystalline cellulose adjustment. The process window is asymmetrical: over-compaction above 1.25 g/cm³ destroys disintegration, while under-compaction below 1.00 g/cm³ increases granule friability and reduces yield on the tablet press. Published data for ribbon solid fraction and SSG efficiency in this specific configuration is limited, but the observed industrial range is sufficient for routine process design.

Capsule disintegration is governed by powder plug porosity below 250 mg fill weight

Hard-shell capsule formulations require sodium starch glycolate to disrupt the powder plug formed inside the shell after the fill station on an automatic capsule machine. At fill weights below 250 mg in size 1 or size 3 hard gelatin capsules, the tamping pins operate with low compression force, typically 10–50 N per station, and the resulting plug has high porosity but low internal cohesiveness. Adding SSG at 4.0–8.0 wt% to a lactose-mannitol or starch-based capsule fill provides rapid water wicking into the plug when the capsule shell dissolves in the disintegration medium at 37±2 °C. The relevant compendial method is USP <701> for hard capsules or Ph. Eur. 2.9.1; the acceptance threshold is complete disintegration within 30 min, but most immediate-release capsule products containing SSG at 6.0 wt% disintegrate within 5–10 min. A process risk unique to capsules is moisture exchange between the fill and the gelatin shell: SSG is hygroscopic and can pull water from the shell when equilibrium relative humidity of the fill is below 35% RH, causing brittle shells and cracking. Conversely, high fill moisture above 60% RH softens the plug and may cause the tamping pins to compress the powder into a dense pellet that no longer disintegrates. The capsule fill should therefore be conditioned to 40–50% RH before filling, and the SSG should be pre-dried at 60 °C for 2–3 h if initial loss on drying exceeds 10.0% (Ph. Eur. 2.2.32). The choice between Type A and Type B SSG affects capsule disintegration because Type A provides faster swelling and higher viscosity in the wetted plug; Type B is less hygroscopic and may be preferred when the API is highly moisture-sensitive. Dissolution of capsule formulations is tested by USP <711> Apparatus II at 50 rpm with a sinker; at SSG levels below 3.0 wt%, the dissolution t80 may exceed 30 min in a model poorly soluble API because the powder plug does not break into primary particles. Filling machines with dosing-disk versus tamping-pin stations produce different plug porosity; tamping-pin pressure at the final station should not exceed 50 N for SSG-containing capsules because over-compression creates a slug that behaves like a compressed tablet, shifting disintegration to 15–25 min. On production-scale capsule lines, the inclusion of 1.0 wt% magnesium stearate in the final blend is acceptable only if blended for 2 min; over-lubrication for more than 5 min has the same hydrophobic effect observed in tablets and can raise capsule disintegration time above 30 min.

In orally disintegrating tablet development, the compression force is deliberately held below 80 N to preserve a porous matrix, so the superdisintegrant load is increased to 5.0–10.0 wt%. A typical placebo platform uses mannitol DC (D50 100–180 µm), microcrystalline cellulose PH101, and crospovidone or SSG Type A. When SSG is used at 7.5 wt% with 40–70 N compression on a single-station instrumented press, the resulting tablets show hardness 30–50 N, friability 0.8–1.5% in USP <1216>, and in vitro disintegration below 30 s in a 10 mL water test at 37 °C. There is no harmonized compendial ODT disintegration method; the USP <701> apparatus can be used with disks and 900 mL water, but ODT products are often tested with a modified 5–10 mL small-volume method to simulate the oral cavity. The main process conflict is friability: high SSG levels above 10.0 wt% absorb moisture from ambient air and weaken the tablet edges, pushing friability above the 1.0% limit typically necessary for blister packaging. The blend should be compressed at room humidity below 45% RH; above 60% RH, loss of tablet hardness and picking may occur. A pre-drying step for SSG at 60 °C for 2 h is recommended when initial loss on drying is above 8.0% (USP <731>). The sensory attributes are also tied to physical form: coarse SSG grades with D50 above 80 µm produce transient grittiness when the tablet contacts saliva, while finer grades below 40 µm improve mouthfeel but increase bulk cohesion and bridging in the feed frame. Low compression force below 30 N may produce tablets that disintegrate rapidly but chip during handling; hardness below 20 N is generally unacceptable for rotary-press scale-up and packaging. Sodium starch glycolate contributes to water absorption ratio values above 5.0 after 10 min immersion in simulated saliva at 37 °C; this is measured by the increase in tablet weight divided by the dry tablet weight. In ODT formulations containing a bitter API, the rapid disintegration of SSG disperses the API particles across the oral cavity and may intensify bitterness; taste-masking by granulation or coating is required before blending with SSG. The use of SSG in ODTs should be evaluated against the presence of mannitol and maltodextrin because these materials compete for available water; wetting-agent concentrations below 0.1% may not be sufficient to ensure rapid hydration in the small saliva volume.

When sodium starch glycolate is screened for sterile injectable or lyophilized matrices, USP <788> particulate limits and endotoxin control override conventional swelling behaviour

Injectable administration imposes a different set of constraints on sodium starch glycolate because the material remains an insoluble, swellable particulate after contact with water. Unlike oral solid dosage forms where disintegration is the desired endpoint, a sterile injectable solution cannot contain visible particles, and subvisible particulate matter is restricted by USP <788> and Ph. Eur. 2.9.19. Sodium starch glycolate as supplied for pharmaceutical oral use is not a sterile material and carries an uncontrolled bioburden; any injectable application would require terminal sterilization or aseptic processing, and the bacterial endotoxin load would need to comply with USP <85> and Ph. Eur. 2.6.14 based on the maximum administered dose per kilogram. In lyophilized or freeze-dried matrices, sodium starch glycolate could serve as a cake-forming or disintegration-enhancing excipient in principle, but the published data for injectable or lyophilized sodium starch glycolate configurations is limited. A major technical barrier is that moist heat sterilization at 121 °C for 15 min hydrolyzes starch ethers and reduces molecular weight and swelling capacity; the resulting degradation products and pH shift must be monitored. Aseptic dry heat sterilization at 160 °C may be less hydrolytic but can cause yellowing and loss of disintegration functionality if the temperature is not uniform. Sterile filtration cannot be used because the particles are not soluble. Therefore, an injectable formulation would require either terminal gamma irradiation at a dose validated to meet a sterility assurance level of 10⁻⁶ under ISO 11137 and USP <71>, or aseptic handling of a pre-sterilized powder with subsequent filling into vials. Even after sterility is achieved, the particle size distribution must be controlled so that no particles exceed the visible inspection threshold under USP <790>; conventional oral-grade SSG has a D90 that may exceed 100 µm, which is incompatible with injectable dispersion. The swelling of SSG in an injectable vehicle at 0.9% sodium chloride solution is suppressed by the ionic strength of the medium, so the material would not generate the same disintegration force observed in deionized water; this is a known limitation of starch glycolate chemistry. At concentrations above 1.0% w/v, the swollen particles increase vehicle viscosity and may interfere with syringeability through needles smaller than 21 G. Because of these constraints, sodium starch glycolate is not regarded as a standard injectable excipient in compendial formulations, and any development programme must treat the material as a novel excipient with full toxicological and particulate qualification. Published data for this specific injectable configuration remains limited; feasibility studies should be anchored to USP <71>, USP <85>, USP <788>, USP <790>, and Ph. Eur. 2.9.19 before evaluating disintegration or release attributes.